Cargando…
Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study
OBJECTIVE: To evaluate potential development of tolerance to adjunctive clobazam in patients with Lennox-Gastaut syndrome. METHODS: Eligible patients enrolled in open-label extension study OV-1004, which continued until clobazam was commercially available in the United States or for a maximum of 2 y...
Autores principales: | Gidal, Barry E., Wechsler, Robert T., Sankar, Raman, Montouris, Georgia D., White, H. Steve, Cloyd, James C., Kane, Mary Clare, Peng, Guangbin, Tworek, David M., Shen, Vivienne, Isojarvi, Jouko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089527/ https://www.ncbi.nlm.nih.gov/pubmed/27683846 http://dx.doi.org/10.1212/WNL.0000000000003253 |
Ejemplares similares
-
Clobazam‐treated patients with Lennox‐Gastaut syndrome experienced fewer seizure‐related injuries than placebo patients during trial OV‐1012
por: Isojarvi, Jouko, et al.
Publicado: (2016) -
Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series
por: Sankar, Raman, et al.
Publicado: (2014) -
Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years
por: Conry, Joan A, et al.
Publicado: (2014) -
Clobazam and Its Use in Epilepsy
por: Pernea, Marius, et al.
Publicado: (2016) -
The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia
por: Ralvenius, William T., et al.
Publicado: (2016)